ELI LILLY & Co is 256.2x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($1.070 T vs $4.18 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DNTH | LLY |
|---|---|---|
| Market cap | $4.18 B | $1.070 T |
| US-listed rank | #1530 | #10 |
| Revenue (latest FY) | $2.04M | $65.18B |
| Net income (latest FY) | -$162.34M | $20.64B |
| Net margin | -7973.3% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 624 | 989 |
ELI LILLY & Co is 256.2x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($1.070 T vs $4.18 B).
In their latest fiscal years, Dianthus Therapeutics, Inc. /DE/ reported $2.04M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Dianthus Therapeutics, Inc. /DE/ and ELI LILLY & Co, or browse the full rankings.